These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36791275)

  • 1. No difference in quality of life between persons with severe haemophilia A and B.
    Kihlberg K; Baghaei F; Bruzelius M; Funding E; Andre Holme P; Lassila R; Nummi V; Ranta S; Gretenkort Andersson N; Berntorp E; Astermark J
    Haemophilia; 2023 Jul; 29(4):987-996. PubMed ID: 36791275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B-NORD study.
    Kihlberg K; Baghaei F; Bruzelius M; Funding E; Andre Holme P; Lassila R; Nummi V; Ranta S; Osooli M; Berntorp E; Astermark J
    Haemophilia; 2021 May; 27(3):366-374. PubMed ID: 33780113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study.
    Oldenburg J; Tran H; Peyvandi F; Núñez R; Trask P; Chebon S; Mahlangu JN; Lehle M; Jiménez-Yuste V; von Mackensen S
    Haemophilia; 2021 May; 27(3):398-407. PubMed ID: 33576546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).
    Mahlangu J; Oldenburg J; Callaghan MU; Shima M; Mancuso ME; Trask P; Recht M; Garcia C; Yang R; Lehle M; Macharia H; Asikanius E; Levy GG; Kruse-Jarres R; von Mackensen S
    Haemophilia; 2019 May; 25(3):382-391. PubMed ID: 31016855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical conditions and risk factors for inhibitor-development in patients with haemophilia: A decade-long prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2).
    Nogami K; Taki M; Matsushita T; Kojima T; Oka T; Ohga S; Kawakami K; Sakai M; Suzuki T; Higasa S; Horikoshi Y; Shinozawa K; Tamura S; Yada K; Imaizumi M; Ohtsuka Y; Iwasaki F; Kobayashi M; Takamatsu J; Takedani H; Nakadate H; Matsuo Y; Matsumoto T; Fujii T; Fukutake K; Shirahata A; Yoshioka A; Shima M;
    Haemophilia; 2022 Sep; 28(5):745-759. PubMed ID: 35689832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life.
    O'Hara J; Walsh S; Camp C; Mazza G; Carroll L; Hoxer C; Wilkinson L
    Health Qual Life Outcomes; 2018 May; 16(1):84. PubMed ID: 29720192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study).
    Måseide RJ; Berntorp E; Astermark J; Olsson A; Bruzelius M; Frisk T; Nummi V; Lassila R; Tjønnfjord GE; Holme PA
    Haemophilia; 2024 Jan; 30(1):98-105. PubMed ID: 37983883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy.
    Itzler R; Buckner TW; Leebeek FWG; Miller J; Recht M; Drelich D; Monahan PE; Pipe SW
    Haemophilia; 2024 May; 30(3):709-719. PubMed ID: 38462823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tailored prophylaxis in children with severe hemophilia: A four-year Iranian study.
    Baghaipour M; Salimi T; Bahoush G; Jazebi M; Ala F; Azizi Saraji A; Dorgalaleh A; Moazezi Nekoei Asl SS; Mohamadamini M; Tabibian S
    Transfus Apher Sci; 2021 Dec; 60(6):103212. PubMed ID: 34257016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining the impact of haemophilia treatment on health-related quality of life.
    Shaikh A; Pedra G; Cawson M; Wiseman C
    Haemophilia; 2022 Sep; 28(5):796-805. PubMed ID: 35537107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world comparative analysis of bleeding complications and health-related quality of life in patients with haemophilia A and haemophilia B.
    Booth J; Oladapo A; Walsh S; O'Hara J; Carroll L; Garcia Diego DA; O'Mahony B
    Haemophilia; 2018 Sep; 24(5):e322-e327. PubMed ID: 30091822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
    Oldenburg J; Mahlangu JN; Bujan W; Trask P; Callaghan MU; Young G; Asikanius E; Peyvandi F; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Xu J; Windyga J; Shima M; von Mackensen S
    Haemophilia; 2019 Jan; 25(1):33-44. PubMed ID: 30427582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
    Skinner MW; Négrier C; Paz-Priel I; Chebon S; Jiménez-Yuste V; Callaghan MU; Lehle M; Niggli M; Mahlangu J; Shapiro A; Shima M; Campinha-Bacote A; Levy GG; Oldenburg J; von Mackensen S; Pipe SW
    Haemophilia; 2021 Sep; 27(5):854-865. PubMed ID: 34171159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Assessment of health-related quality of life in psoriasis patients in Hungary].
    Poór AK; Sárdy M; Cserni T; Brodszky V; Holló P; Gulácsi L; Remenyik É; Szegedi A; Rencz F; Péntek M
    Orv Hetil; 2018 May; 159(21):837-846. PubMed ID: 29779387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Social/economic costs and quality of life in patients with haemophilia in Europe.
    Cavazza M; Kodra Y; Armeni P; De Santis M; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Gulácsi L; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():53-65. PubMed ID: 27048374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the relationship between condition severity and health-related quality of life in people with haemophilia A across Europe: a multivariable analysis of data from the CHESS II study.
    Ferri Grazzi E; Hawes C; Camp C; Hinds D; O'Hara J; Burke T
    Health Qual Life Outcomes; 2024 Jul; 22(1):58. PubMed ID: 39075533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B.
    Burke T; Shaikh A; Ali TM; Li N; Curtis R; Garcia Diego DA; Recht M; Sannie T; Skinner M; O'Hara J
    J Med Econ; 2022; 25(1):386-392. PubMed ID: 35253589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of joint disease, inhibitors and other complications on health-related quality of life among males with severe haemophilia A in the United States.
    Soucie JM; Grosse SD; Siddiqi AE; Byams V; Thierry J; Zack MM; Shapiro A; Duncan N;
    Haemophilia; 2017 Jul; 23(4):e287-e293. PubMed ID: 28574229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of severe haemophilia A on patients' health status: results from the guardian(™) 1 clinical trial of turoctocog alfa (NovoEight(®) ).
    Ozelo M; Chowdary P; Regnault A; Busk AK
    Haemophilia; 2015 Jul; 21(4):451-7. PubMed ID: 25677761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement properties of the Haem-A-QoL in haemophilia clinical trials.
    von Mackensen S; Eldar-Lissai A; Auguste P; Krishnan S; von Maltzahn R; Yu R; Wyrwich KW
    Haemophilia; 2017 May; 23(3):383-391. PubMed ID: 28026074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.